Compounds of the formula I:
or pharmaceutically acceptable salts thereof,
wherein R
1
, R
2
, R
3
and R
4
are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).
[EN] PIPERAZINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLU5 RECEPTORS<br/>[FR] DÉRIVÉS DE PIPÉRAZINE ET LEUR UTILISATION À TITRE DE MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MGLUR5
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2013087805A1
公开(公告)日:2013-06-20
This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R1, R2, R3, R4, Q have meanings given in the description.
[EN] SK AND IK CHANNEL AGONISTS FOR TREATMENT OF HEART FAILURE<br/>[FR] AGENTS AGONISTES DES CANAUX SK ET IK POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE
申请人:UNIV COLUMBIA
公开号:WO2016191294A1
公开(公告)日:2016-12-01
The present invention provides compounds that are improved potassium channel agonists. Pharmaceutical compositions including a pharmaceutically acceptable carrier and a compound of the present invention are also provided. Methods and kits for treating or ameliorating the effects of heart failure syndrome, high blood pressure and diabetes also are provided. Methods, kits and compositions which include compounds of the present invention also are provided.
Assessment of the rules related to gaining activity against Gram-negative bacteria
作者:Henni-Karoliina Ropponen、Eleonora Diamanti、Alexandra Siemens、Boris Illarionov、Jörg Haupenthal、Markus Fischer、Matthias Rottmann、Matthias Witschel、Anna K. H. Hirsch
DOI:10.1039/d0md00409j
日期:——
Evaluation of the applicability of Gram-negative activity rules using 16 amino acid modified compounds against a panel of Escherichia coli and its mutant strains.
评估使用16种氨基酸修饰化合物对一系列大肠杆菌及其突变菌株适用的革兰氏阴性活性规则。
AQUEOUS SILICONE POLYMER COMPOSITIONS
申请人:Momentive Performance Materials GmbH
公开号:EP3501488A1
公开(公告)日:2019-06-26
The present invention relates to aqueous compositions comprising one or more silicones and a synergistic combination of anti-microbiological agents, to a process for preparing the aqueous compositions, and to the use of said aqueous compositions, in particular, for the manufacture of home care articles, household cleansing articles, fabric articles, cosmetic articles, hygienic articles, medical articles etc.